Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC).


Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
14 12 2019
Historique:
received: 14 12 2018
revised: 17 01 2019
accepted: 08 03 2019
pubmed: 26 3 2019
medline: 23 10 2020
entrez: 26 3 2019
Statut: ppublish

Résumé

Reducing maternal mortality is a World Health Organization (WHO) global health goal. Although maternal deaths due to haemorrhage and infection are declining, those related to heart disease are increasing and are now the most important cause in western countries. The aim is to define contemporary diagnosis-specific outcomes in pregnant women with heart disease. From 2007 to 2018, pregnant women with heart disease were prospectively enrolled in the Registry Of Pregnancy And Cardiac disease (ROPAC). Primary outcome was maternal mortality or heart failure, secondary outcomes were other cardiac, obstetric, and foetal complications. We enrolled 5739 pregnancies; the mean age was 29.5. Prevalent diagnoses were congenital (57%) and valvular heart disease (29%). Mortality (overall 0.6%) was highest in the pulmonary arterial hypertension (PAH) group (9%). Heart failure occurred in 11%, arrhythmias in 2%. Delivery was by Caesarean section in 44%. Obstetric and foetal complications occurred in 17% and 21%, respectively. The number of high-risk pregnancies (mWHO Class IV) increased from 0.7% in 2007-2010 to 10.9% in 2015-2018. Determinants for maternal complications were pre-pregnancy heart failure or New York Heart Association >II, systemic ejection fraction <40%, mWHO Class 4, and anticoagulants use. After an increase from 2007 to 2009, complication rates fell from 13.2% in 2010 to 9.3% in 2017. Rates of maternal mortality or heart failure were high in women with heart disease. However, from 2010, these rates declined despite the inclusion of more high-risk pregnancies. Highest complication rates occurred in women with PAH.

Identifiants

pubmed: 30907409
pii: 5419276
doi: 10.1093/eurheartj/ehz136
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3848-3855

Commentaires et corrections

Type : CommentIn

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Jolien Roos-Hesselink (J)

Department of Cardiology, Erasmus Medical Center, CA Rotterdam, The Netherlands.
EURObservational Research Programme, European Society of Cardiology, 2035 route des Colles les Templiers, Sophia Antipolis, France.

Lucia Baris (L)

Department of Cardiology, Erasmus Medical Center, CA Rotterdam, The Netherlands.

Mark Johnson (M)

Department of Obstetric Medicine, Imperial College London, Kensington, London, UK.

Julie De Backer (J)

Department of Cardiology, Ghent University Hospital, Corneel Heymanslaan 10, Ghent, Belgium.

Catherine Otto (C)

Department of Cardiology, UW School of Medicine, 1959 NE Pacific St, Seattle, WA, USA.

Ariane Marelli (A)

Department of Cardiology, McGill University Faculty of Medicine, 3605 Rue de la Montagne, Montréal, QC, Canada.

Guillaume Jondeau (G)

Department of Cardiology, Bichat-Claude Bernard Hospital, 46 Rue Henri Huchard, Paris, France.

Werner Budts (W)

Department of Cardiology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.

Jasmine Grewal (J)

Department of Cardiology, University of British Columbia, Faculty of Medicine, 2312 Pandosy St, Kelowna, BC, Canada.

Karen Sliwa (K)

Hatter Institute for Cardiovascular Research in Africa, Faculty of Health Sciences, University of Cape Town, Private Bag X3 7935, Observatory, South Africa.

William Parsonage (W)

Department of Cardiology, Royal Brisbane and Women's Hospital, Cnr Butterfield St and Bowen Bridge Road, Herston, QLD 4029, Australia.

Aldo P Maggioni (AP)

EURObservational Research Programme, European Society of Cardiology, 2035 route des Colles les Templiers, Sophia Antipolis, France.
National Association of Hospital Cardiologists Research Center (ANMCO), Florence, Italy.

Iris van Hagen (I)

Department of Cardiology, Erasmus Medical Center, CA Rotterdam, The Netherlands.

Alec Vahanian (A)

EURObservational Research Programme, European Society of Cardiology, 2035 route des Colles les Templiers, Sophia Antipolis, France.
Department of Cardiology, Bichat-Claude Bernard Hospital, 46 Rue Henri Huchard, Paris, France.

Luigi Tavazzi (L)

Department of Cardiology, Maria Cecilia Hospital, Via Madonna di Genova, 1, 48033 Cotignola RA, Italy.

Uri Elkayam (U)

Department of Obstetrics and Gynaecology, University of Southern California, Keck School of Medicine, 1975 Zonal Ave, Los Angeles, CA, USA.

Eric Boersma (E)

Department of Cardiology, Erasmus Medical Center, CA Rotterdam, The Netherlands.

Roger Hall (R)

Department of Cardiology, University of East Anglia, Faculty of Medicine, Norwich Research Park, Norwich, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH